Dr. Reddy's Laboratories Ltd. (RDY)

$70.92

-0.57

(-0.8%)▲

Market is closed - opens 7 PM, 25 Apr 2024

Performance

  • $70.87
    $71.59
    $70.92
    downward going graph

    0.07%

    Downside

    Day's Volatility :1.01%

    Upside

    0.94%

    downward going graph
  • $52.33
    $77.72
    $70.92
    downward going graph

    26.21%

    Downside

    52 Weeks Volatility :32.67%

    Upside

    8.75%

    downward going graph

Returns

PeriodDr. Reddy's Laboratories Ltd.
3 Months
2.09%
6 Months
7.28%
1 Year
19.66%
3 Years
4.51%

Highlights

Market Capitalization
11.9B
Book Value
$1608.58
Dividend Share
40.0
Dividend Yield
0.68%
Earnings Per Share (EPS)
3.76
PE Ratio
19.01
PEG Ratio
4.71
Wall Street Target Price
80.06
Profit Margin
19.24%
Operating Margin TTM
24.74%
Return On Assets TTM
12.38%
Return On Equity TTM
21.39%
Revenue TTM
271.3B
Revenue Per Share TTM
272.46
Quarterly Revenue Growth YOY
6.6000000000000005%
Gross Profit TTM
113.8B
EBITDA
81.0B
Diluted Eps TTM
3.76
Quarterly Earnings Growth YOY
0.1
EPS Estimate Current Year
3.8
EPS Estimate Next Year
3.97
EPS Estimate Current Quarter
0.85
EPS Estimate Next Quarter
0.63

Analyst Recommendation

Buy
    53%Buy
    23%Hold
    23%Sell
Based on 43 Wall street analysts offering stock ratings for Dr. Reddy's Laboratories Ltd.(by analysts ranked 0 to 5 stars)
Based on 43 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
23
23
24
Hold
10
10
10
Sell
10
10
10

Analyst Forecast

What analysts predicted

Upside of 12.89%

Current $70.92
Target $80.06

Company Financials

FY18Y/Y Change
Revenue
142.0B
↑ 0.87%
Net Income
9.8B
↓ 18.55%
Net Profit Margin
6.9%
↓ 1.65%
FY19Y/Y Change
Revenue
2.2B
↑ 8.32%
Net Income
270.7M
↑ 91.67%
Net Profit Margin
12.22%
↑ 5.32%
FY20Y/Y Change
Revenue
2.3B
↑ 13.49%
Net Income
258.9M
↑ 3.74%
Net Profit Margin
11.17%
↓ 1.05%
FY21Y/Y Change
Revenue
2.6B
↑ 8.66%
Net Income
235.5M
↓ 11.59%
Net Profit Margin
9.09%
↓ 2.08%
FY22Y/Y Change
Revenue
2.8B
↑ 13.0%
Net Income
310.8M
↑ 36.72%
Net Profit Margin
10.99%
↑ 1.9%
FY23Y/Y Change
Revenue
3.0B
↑ 14.69%
Net Income
548.9M
↑ 91.22%
Net Profit Margin
18.33%
↑ 7.34%
Q3 FY22Q/Q Change
Revenue
773.9M
↑ 20.91%
Net Income
136.6M
↓ 6.3%
Net Profit Margin
17.65%
↓ 5.12%
Q4 FY22Q/Q Change
Revenue
818.7M
↑ 7.36%
Net Income
150.8M
↑ 12.07%
Net Profit Margin
18.42%
↑ 0.77%
Q1 FY23Q/Q Change
Revenue
767.0M
↓ 6.99%
Net Income
116.8M
↓ 23.09%
Net Profit Margin
15.23%
↓ 3.19%
Q2 FY23Q/Q Change
Revenue
820.8M
↑ 7.01%
Net Income
170.8M
↑ 46.22%
Net Profit Margin
20.81%
↑ 5.58%
Q3 FY23Q/Q Change
Revenue
68.8B
↑ 2.1%
Net Income
14.8B
↑ 5.53%
Net Profit Margin
21.51%
↑ 0.7%
Q4 FY23Q/Q Change
Revenue
72.1B
↑ 4.86%
Net Income
13.8B
↓ 6.83%
Net Profit Margin
19.11%
↓ 2.4%
FY18Y/Y Change
Total Assets
225.6B
↑ 2.63%
Total Liabilities
99.1B
↑ 3.52%
FY19Y/Y Change
Total Assets
3.2B
↓ 0.08%
Total Liabilities
1.2B
↓ 14.03%
FY20Y/Y Change
Total Assets
3.1B
↑ 3.02%
Total Liabilities
1.0B
↓ 9.36%
FY21Y/Y Change
Total Assets
3.6B
↑ 14.32%
Total Liabilities
1.2B
↑ 17.16%
FY22Y/Y Change
Total Assets
3.9B
↑ 11.74%
Total Liabilities
1.4B
↑ 17.25%
FY23Y/Y Change
Total Assets
3.9B
↑ 8.83%
Total Liabilities
1.1B
↓ 15.21%
Q3 FY22Q/Q Change
Total Assets
3.6B
↓ 1.69%
Total Liabilities
1.0B
↓ 11.34%
Q4 FY22Q/Q Change
Total Assets
3.7B
↑ 6.3%
Total Liabilities
629.4M
↓ 38.59%
Q1 FY23Q/Q Change
Total Assets
3.9B
↑ 4.38%
Total Liabilities
1.1B
↑ 72.9%
Q2 FY23Q/Q Change
Total Assets
4.1B
↑ 3.78%
Total Liabilities
674.4M
↓ 38.48%
Q3 FY23Q/Q Change
Total Assets
347.0B
↑ 3.58%
Total Liabilities
93.9B
↑ 69.67%
Q4 FY23Q/Q Change
Total Assets
372.8B
↑ 7.44%
Total Liabilities
105.0B
↑ 11.77%
FY18Y/Y Change
Operating Cash Flow
18.0B
↓ 16.19%
Investing Cash Flow
-14.9B
↓ 19.43%
Financing Cash Flow
-4.4B
↑ 20.26%
FY19Y/Y Change
Operating Cash Flow
413.4M
↑ 59.21%
Investing Cash Flow
-111.3M
↓ 48.08%
Financing Cash Flow
-307.2M
↑ 380.32%
FY20Y/Y Change
Operating Cash Flow
396.2M
↑ 3.96%
Investing Cash Flow
-65.4M
↓ 36.29%
Financing Cash Flow
-334.0M
↑ 17.97%
FY21Y/Y Change
Operating Cash Flow
487.7M
↑ 19.64%
Investing Cash Flow
-309.5M
↑ 360.29%
Financing Cash Flow
-4.1M
↓ 98.82%
FY22Y/Y Change
Operating Cash Flow
370.7M
↓ 21.27%
Investing Cash Flow
-348.0M
↑ 16.45%
Financing Cash Flow
-31.9M
↑ 712.75%
FY23Y/Y Change
Operating Cash Flow
717.1M
↑ 109.45%
Investing Cash Flow
-503.9M
↑ 56.79%
Financing Cash Flow
-327.2M
↑ 1009.04%
Q3 FY22Q/Q Change
Operating Cash Flow
113.9M
↑ 39.46%
Investing Cash Flow
70.4M
↓ 216.45%
Financing Cash Flow
-151.5M
↑ 14.31%
Q4 FY22Q/Q Change
Operating Cash Flow
281.3M
↑ 150.62%
Investing Cash Flow
-309.6M
↓ 546.54%
Financing Cash Flow
7.0M
↓ 104.72%
Q1 FY23Q/Q Change
Operating Cash Flow
239.7M
↓ 15.4%
Investing Cash Flow
-503.9M
↑ 61.61%
Financing Cash Flow
-52.4M
↓ 837.22%
Q2 FY23Q/Q Change
Operating Cash Flow
137.0M
↓ 42.83%
Investing Cash Flow
-55.0M
↓ 89.08%
Financing Cash Flow
-18.0M
↓ 65.66%
Q3 FY23Q/Q Change
Operating Cash Flow
17.9B
↑ 59.34%
Investing Cash Flow
-12.8B
↑ 182.33%
Financing Cash Flow
-7.0B
↑ 376.69%

Technicals Summary

Sell

Neutral

Buy

Dr. Reddy's Laboratories Ltd. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Dr. Reddy's Laboratories Ltd.
Dr. Reddy's Laboratories Ltd.
-3.39%
7.28%
19.66%
4.51%
71.1%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-0.91%
28.4%
35.75%
40.71%
78.24%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-0.95%
1.58%
-4.79%
12.69%
12.69%
Zoetis Inc.
Zoetis Inc.
-10.09%
-7.81%
-12.8%
-11.14%
48.17%
Viatris Inc.
Viatris Inc.
-2.37%
28.76%
25.82%
-14.76%
-29.31%
Catalent, Inc.
Catalent, Inc.
-0.8%
41.9%
32.08%
-51.64%
25.36%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Dr. Reddy's Laboratories Ltd.
Dr. Reddy's Laboratories Ltd.
19.01
19.01
4.71
3.8
0.21
0.12
0.01
1608.58
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
56.72
56.72
0.44
4.78
0.13
0.09
NA
22.61
Haleon Plc Spon Ads
Haleon Plc Spon Ads
30.04
30.04
1.69
0.45
0.07
0.04
0.03
1.8
Zoetis Inc.
Zoetis Inc.
29.5
29.5
2.58
5.8
0.5
0.13
0.01
10.9
Viatris Inc.
Viatris Inc.
225.0
225.0
NA
2.78
0.0
0.03
0.04
17.05
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.48
-0.3
-0.01
NA
20.41
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Dr. Reddy's Laboratories Ltd.
Dr. Reddy's Laboratories Ltd.
Buy
$11.9B
71.1%
19.01
19.24%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.1B
78.24%
56.72
13.23%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$38.4B
12.69%
30.04
9.28%
Zoetis Inc.
Zoetis Inc.
Buy
$68.3B
48.17%
29.5
27.43%
Viatris Inc.
Viatris Inc.
Hold
$13.4B
-29.31%
225.0
0.35%
Catalent, Inc.
Catalent, Inc.
Hold
$10.1B
25.36%
211.02
-31.77%

Institutional Holdings

  • Goldman Sachs Group Inc

    2.21%

  • BlackRock Inc

    1.80%

  • Royal Bank of Canada

    1.33%

  • Renaissance Technologies Corp

    1.12%

  • Robeco Institutional Asset Management BV

    1.04%

  • Aikya Investment Management Ltd

    0.66%

Corporate Announcements

  • Dr. Reddy's Laboratories Ltd. Dividends December,2023

    In the quarter ending December,2023. Dr. Reddy's Laboratories Ltd. has declared dividend of $0.49

    Read More

Company Information

They are an Indian multinational pharmaceutical company located in Hyderabad, Telangana, India. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited.

Organization
Dr. Reddy's Laboratories Ltd.
Employees
25863
CEO
Mr. Gunupati Venkateswara Prasad B.E.
Industry
Health Technology

Discover More

FAQs